Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges

Glioblastoma is the most common and lethal primary brain malignancy. Despite major investments in research into glioblastoma biology and drug development, treatment remains limited and survival has not substantially improved beyond 1–2 years. Cancer stem cells (CSC) or glioma stem cells (GSC) refer...

Descripción completa

Detalles Bibliográficos
Autores principales: Piper, Keenan, DePledge, Lisa, Karsy, Michael, Cobbs, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945033/
https://www.ncbi.nlm.nih.gov/pubmed/33718170
http://dx.doi.org/10.3389/fonc.2021.615704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945033/
https://www.ncbi.nlm.nih.gov/pubmed/33718170
http://dx.doi.org/10.3389/fonc.2021.615704

Ejemplares similares